Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to MYELOMA


Selecting CAR T-cell Therapy for Patients with Late Relapsed Multiple Myeloma

Hematology March 6th 2023

The New England Journal of Medicine

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Oncology, Medical February 21st 2023

JCI Insight

Heterogeneity of B-cell Lymphopoiesis in Patients with Premalignant and Active Myeloma

Hematology February 13th 2023


Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial

Hematology January 23rd 2023

The New England Journal of Medicine

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Hematology December 19th 2022

MedPage Today

Myeloma Patients Who Relapse After CAR T-Cell Therapy Have Options

Hematology November 14th 2022

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form